Log In or Register to Join The Conversation!

This topic has 3 replies, 3 voices, and was last updated 2 years, 4 months ago by Kevin Schaefer.

  • Author
    Posts
    • #16027
      Michael Morale
      Keymaster

      In this episode of the Morale Monologue, I’m going to read an article that was posted to the Cure SMA website on Monday, December 3, 2018. The article is entitled Novartis Announces FDA Filing Acceptance and Priority Review For AVXS-101. As most of you know, Biogen was awarded Fast-Track status by the FDA for their drug Spinraza. Avexis’s drug AVXS-101, now known as ZOLGENSMA, was awarded Priority Review designation, which is essentially the same thing as Fast-Track status. The once anticipated acceptance by the FDA was due between June and September of 2019, but since they were awarded Priority Review designation, ZOLGENSMA is now anticipated to receive final approval by the FDA in May 2019. Priority Review designation means the FDA’s goal is to take action on an application within six months, compared to 10 months under standard review.

      I am reading the article verbatim from the Cure SMA website, and a link to this article can be found just here: Cure SMA Article: http://www.curesma.org/news/novartis-avexis-bla-acceptance.html

       

      Be sure to subscribe to the SMA News Today YouTube channel so that you don’t miss an episode of this vlog, and you can also connect with me right here on the forums page.

    • #16056
      Kevin Schaefer
      Keymaster

      Thanks Michael! It’s definitely an exciting time for the SMA community. I wrote about this topic as well in my latest column: https://smanewstoday.com/2018/12/11/sma-research-advancements-grateful-patience/?amp.

    • #16087
      Adnan Hafizovic
      Participant

      But this cure is just for people with type 1?

Viewing 2 reply threads
  • You must be logged in to reply to this topic.

©2021 KLEO Template a premium and multipurpose theme from Seventh Queen

CONTACT US

We're not around right now. But you can send us an email and we'll get back to you, asap.

Sending
or

Log in with your credentials

or    

Forgot your details?

or

Create Account

Copyright © 2017-2021 All rights reserved.